Here, we demonstrate that expression of the clinically relevant activation-associated AKT mutant protein AKT-E17K increased cellular antioxidant capacity, particularly cellular GSH levels, and thereby enhanced radioresistance of TrC1 prostate cancer cells. The gene discussed is AKT1; the disease is prostate cancer.